About Us
Services and Providers
Health Resources
Clarian Arnett Hospital
Press Area
Referral Zone
Provider Recruitment
Employment
Foundation
Clarian Health
Contact Us

Cancer Care

Current Clinical Trial List | updated 08.26.08

Bladder Cancer -

  • Phase II Trial Of Cisplatin, Gemcitabine and Bevacizumab in Combination For Metastatic Transitional Cell Cancer.

Breast Cancer -

  • Quality of Life in Younger Breast Cancer Survivors. (Local IRB)
  • A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer
  • Program For The Assessment Of Clinical Cancer Tests (Pacct-1) Trial Assigning Individualized Options For Treatment: The TAILORx Trial.
  • Phase III Trial OF Bisphosphonates as Adjuvant Therapy For Primary Breast Cancer. (STAGES I, II, III)
  • A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-Expressing Metastatic Breast Cancer.
  • A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
  • Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy For Post Menopausal Women With Metastatic Breast Cancer.
  • Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study.

Colorectal Cancer -

  • A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers. (NCI CIRB).

  • A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer.

Esophageal Cancer -

  • A Phase II Study Of Temozolomide (SCH 52365) in Subjects With Advanced Aerodigestive Tract Cancers Selected for Methylation Of O6 –Methyl-Guanine-DNA Methyl Transferase (MGMT) Promoter.

Head & Neck Cancer -

  • A Phase II Study Of Temozolomide (SCH 52365) in Subjects With Advanced Aerodigestive Tract Cancers Selected for Methylation Of O6 –Methyl-Guanine-DNA Methyl Transferase (MGMT) Promoter.

Lung Cancer -

  • A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (>4cm) –IIIA Non-Small Cell Lung Cancer (NSCLC)
  • Randomized Phase II Study of Docetaxel or Pemetrexed with or without Cetuximab in Patients with Recurrent or Progressive Non-Small Cell Lung Cancer after Platinum-Based Therapy.
  • A Phase II Study Of Temozolomide (SCH 52365) in Subjects With Advanced Aerodigestive Tract Cancers Selected for Methylation Of O6 –Methyl-Guanine-DNA Methyl Transferase (MGMT) Promoter.

Lymphoma -

  • A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Lenalidomide (REVLIMID) in Combination with Dexamethasone in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
  • A Phase II Study of Enzastaurin in Patients with Follicular Lymphoma.

Myelodysplastic Syndrome -

  • A Phase II Randomized Trial with a Modified Dose and Schedule of Subcutaneously Administered Azacitidine and Erythropoietin versus Azacitidine Alone in Patients with Low-Risk Myelodysplastic Syndromes (Less than 11% Marrow and Peripheral Blood Blasts).

Multiple Myeloma -

  • Randomized Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE (Bortezomib), Thalidomide, and Dexamethasone (VTD) versus VELCADE and Dexamethasone (VD) versus VELCADE, Melphalan, and Prednisone (VMP).

Ovarian Cancer -

  • A Phase I/II Study of Sorafenib in Combination with Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis.

Prostate Cancer -

  • Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients With Advanced Hormone Refractory Prostate Cancer.

Renal Cancer -

  • ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carninoma.

Prevention Trials:

  • “Prevention of Cataract and Age-Related Macular Degeneration With Vitamin E and Selenium 0 SELECT Eye Endpoints (SEE), Phase III Ancillary to S0000 – SELECT”.

Miscellaneous:

  • A Phase II Study Of Temozolomide (SCH 52365) in Subjects With Advanced Aerodigestive Tract Cancers Selected for Methylation Of O6 –Methyl-Guanine-DNA Methyl Transferase (MGMT) Promoter.
  • The Effectiveness of Guided Imagery and Relaxation in Reducing Bone Cancer or Bone Metastasis Pain: A Pilot Study
Providers
Research
Education
Treatment
Prevention
Support Services
Physician Referral
Location
Links

About Us | Services & Providers | Health Resources | Clarian Arnett Hospital
Press Area | Referring Providers | Provider Recruitment | Employment
Foundation | Contact Us

Copyright © 2007, Clarian Arnett Health. All rights reserved.
View our privacy statement.
Notificacion de las Practicas de Privacidad